28th Conference on Retroviruses and Opportunistic Infections (CROI 2021) virtual
1 June 2021. Related: Conference reports.
CROI 28 (virtual) 2021
Dolutegravir-based regimens safe and effective in pregnancy and postpartum
1 June 2021. Related: Conference reports, Pregnancy.
Dolutegravir superior to standard of care in children and adolescents: results from the ODYSSEY trial
1 June 2021. Related: Conference reports, Paediatric care.
CROI 2021: First results using capsid inhibitor lenacapavir against MDR HIV: potential for six-monthly ART and PrEP
1 April 2021. Related: Conference reports, Antiretrovirals.
CROI 2021: Pregnancy outcomes and weight gain with dolutegravir and TAF
1 April 2021. Related: Conference reports, Pregnancy.
CROI 2021: New compounds for prevention and treatment of COVID-19
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Oral molnupiravir at higher dose reduces SARS-CoV-2 viral load at day five in small phase 2 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Bamlanivimab prophylaxis reduces hospitalisation and mortality: results from phase 3 BLAZE-2 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Dual Eli-Lilly mAb bamlanivimab and etesevimab reduces hospitalisation after single infusion: results from BLAZE-1 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Dual Regeneron mAbs casirivimab with imdevimab reduce transmission: interim results from phase 3 study
1 April 2021. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
CROI 2021: Presentations from the LEAP workshop 2021
1 April 2021. Related: Conference reports, Other news.
CROI 2021: Presentations on NATAP.org
1 April 2021. Related: Conference reports, Other news.
28th Conference on Retroviruses and Opportunistic Infections (CROI 2021)
12 March 2021. Related: Conference reports.
CROI 2021: Urgency of global access to vaccines, the potential of mAbs and the lessons learned from HIV
12 March 2021. Related: Conference reports, COVID-19: treatment access, COVID-19: investigational drugs, COVID-19.
CROI 2021: Community challenge 6-month CROI pay wall – rather than usual open access…
12 March 2021. Related: Conference reports, Other news.
CROI 2021: Once-daily GSK254 maturation inhibitor as treatment for HIV multidrug resistance
12 March 2021. Related: Conference reports, Antiretrovirals.
CROI 2021: Dosing for once-weekly oral ART: islatravir plus MK-8507 studies due to start in 2021
12 March 2021. Related: Conference reports, Antiretrovirals.
CROI 2021: Islatravir dosing for once-monthly and annual PrEP: if effective this could end HIV transmission
12 March 2021. Related: Conference reports, HIV prevention and transmission.
CROI 2021: Dolutegravir with recycled tenofovir and lamivudine performs well second-line: primary results from the NADIA trial
12 March 2021. Related: Conference reports, Treatment strategies.
CROI 2021: HIV capsid uncoats in the CD4 nucleus rather than the cytoplasm – viral lifecycle updated…
12 March 2021. Related: Conference reports, Virology.
CROI 2021: Community HIV cure workshops online
12 March 2021. Related: Conference reports, Cure-related research.